Drugs / Bone Marrow Derived Autologous CD133+ Selected Cell Product
Bone Marrow Derived Autologous CD133+ Selected Cell Product
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03043742 | Jul 2016 → Nov 2020 | myocardial ischemia | Michael Sekela | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bone Marrow Derived Autologous CD133+ Selected Cell Product | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03043742 ↗ |
| Modality | Cell therapy | “CD133+ BM-derived stem cells” NCT03043742 ↗ |
| Route | Other | “Injection of bone marrow derived autologous CD133+ cell product into laser channels” NCT03043742 ↗ |